BioMed Research International / 2016 / Article / Tab 6

Research Article

A Retrospective Observational Study to Assess Prescription Pattern in Patients with Type B Aortic Dissection and Treatment Outcome

Table 6

Univariable and multivariable analysis for primary endpoint.

VariablesCrude HR (95% CI) valueAdjusted HR (95% CI) value

Treatment strategy
 Monotherapyrefref
 None3.31 (0.64–17.22)0.156 4.19 (0.54–32.31)0.169
 Dual therapy1.12 (0.24–5.28)0.886 1.66 (0.23–12.03)0.614
 Triple therapy1.45 (0.33–6.51)0.624 2.88 (0.41–20.35)0.290
 Quadruple therapy1.07 (0.18–6.39)0.944 2.01 (0.22–18.23)0.535
Age (year)1.01 (0.98–1.04)0.475 1.00 (0.95–1.04)0.831
Sex
 Femalerefref
 Male0.96 (0.37–2.51)0.937 1.43 (0.39–5.22)0.587
Baseline maximum aortic diameter (cm)2.11 (1.38–3.23)<0.0012.91 (1.70–4.99)<0.001
Current smoker1.13 (0.55–2.35)0.740 0.89 (0.33–2.39)0.810
BMI1.00 (0.93–1.08)0.974 0.98 (0.89–1.08)0.679
Comorbidities (before index day 1 year)
 Hyperlipidemia1.15 (0.47–2.82)0.763 1.33 (0.42–4.18)0.627
 Hypertension0.95 (0.22–4.00)0.940 0.29 (0.05–1.71)0.169
 Diabetes mellitus1.06 (0.40–2.80)0.901 1.05 (0.32–3.44)0.931
 COPD1.63 (0.67–4.00)0.283 1.03 (0.26–4.02)0.966
 Heart failure2.04 (0.71–5.85)0.187 0.97 (0.22–4.28)0.964
 Coronary artery disease 1.68 (0.69–4.10)0.258 2.06 (0.49–8.70)0.326
 Cerebrovascular disease0.97 (0.34–2.78)0.952 0.46 (0.13–1.66)0.237
 Chronic kidney disease1.90 (0.77–4.65)0.161 2.16 (0.68–6.84)0.193
 Cancer1.55 (0.47–5.17)0.472 2.10 (0.48–9.25)0.326
Poor blood pressure and heart rate control
 Poor blood pressure control0.94 (0.36–2.46)0.892 0.63 (0.20–1.99)0.431
 Poor heart rate control0.99 (0.35–2.85)0.990 0.68 (0.16–2.88)0.600

HR: hazard ratio; CI: confidence interval; BMI: body mass index; COPD: chronic obstructive pulmonary disease.
Adjusted for treatment strategy, age, sex, initial maximum aortic diameter, current smoker, BMI, all of comorbidity, poor blood pressure, and poor heart rate control.
.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.